Comparison
17 20 Lyase Deficiency Isolated C3277849 vs 14q11 2 Microduplication Syndrome C4749855
Clinical comparison between 17 20 Lyase Deficiency Isolated and 14q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
14q11 2 Microduplication Syndrome C4749855
A rare genetic condition involving a small extra piece of chromosome 14. Features vary and may include developmental delays. Management focuses on supportive therapies and monitoring.
6 comparison axes
Onset
17 20 Lyase Deficiency Isolated C3277849
0-18
14q11 2 Microduplication Syndrome C4749855
0-5
Onset patterns differ
Severity
17 20 Lyase Deficiency Isolated C3277849
severe
14q11 2 Microduplication Syndrome C4749855
moderate
Different severity levels
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
14q11 2 Microduplication Syndrome C4749855
Chronic
Differing course
Communicable
17 20 Lyase Deficiency Isolated C3277849
No
14q11 2 Microduplication Syndrome C4749855
No
Different transmission
Body System
17 20 Lyase Deficiency Isolated C3277849
endocrine
14q11 2 Microduplication Syndrome C4749855
congenital
Same/different system
Category
17 20 Lyase Deficiency Isolated C3277849
endocrine
14q11 2 Microduplication Syndrome C4749855
genetic
Different category
Bottom line
17-20-lyase-deficiency-isolated-C3277849 and 14q11-2-microduplication-syndrome-C4749855 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 20 Lyase Deficiency Isolated C3277849 | 14q11 2 Microduplication Syndrome C4749855 | Discriminating power |
|---|---|---|---|
| Sexual development | May impair development of sexual characteristics in males or females. | Not described as a primary sex-hormone disorder; features vary. | High |
| Developmental delay | Not established from the supplied description. | May include developmental delays, but the pattern is variable. | Moderate |
| Age at recognition | Reported onset range is childhood through adolescence. | Reported onset range is early childhood. | Low |
When to favor each condition
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development with suspected steroidogenic defect
The supplied description centers on impaired sex-hormone production.
Moderate
Endocrine rather than chromosomal presentation
The listed category and body system are endocrine.
Moderate
Need for hormone-replacement planning
Treatment is described as hormone supplementation, with doses individualized.
Moderate
Choose 14q11 2 Microduplication Syndrome C4749855 when
Early-childhood developmental concerns with suspected copy-number change
The condition is a chromosomal microduplication with variable developmental features.
Moderate
Congenital or genetic evaluation
The listed system is congenital and the category is genetic.
Moderate
Need for supportive therapy and monitoring
Management is described as supportive rather than hormone-specific.
Moderate
How key tests differ
| Test | 17 20 Lyase Deficiency Isolated C3277849 | 14q11 2 Microduplication Syndrome C4749855 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | May show a pattern suggesting impaired sex-hormone synthesis; exact cutoffs are not supplied. | No characteristic steroid abnormality is established here. | An abnormal profile supports endocrine evaluation but is not itself a diagnosis. |
| Chromosomal microarray | Not expected to define this enzyme disorder. | May identify a 14q11.2 duplication when clinically indicated. | A copy-number finding requires laboratory and clinician correlation. |
| Targeted genetic or enzyme assessment | May be considered to evaluate the suspected enzymatic pathway. | Does not replace chromosomal testing for a microduplication. | Test selection depends on phenotype; results need specialist interpretation. |
Prognosis comparison
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic endocrine condition; specific mortality or fertility outcomes are not established here.
- Factors
- Hormone management, age at recognition, and associated clinical findings.
14q11 2 Microduplication Syndrome C4749855
- Outcome
- Chronic condition with variable developmental impact; exact prognosis is not established.
- Factors
- Duplication findings, developmental profile, and access to supportive care.
Time frame: Childhood onward, with individualized long-term follow-up.
Clinician interpretation is required because source data are sparse.
Complications comparison
| Complication | Presentation |
|---|---|
| Pubertal or reproductive effects | Possible because sex-hormone production is impaired. Not established as a defining complication. Individual outcomes vary and require endocrine assessment. |
| Developmental or learning needs | Not established from the supplied source. May occur and can vary in extent. Support should be based on assessed function, not diagnosis alone. |
| Long-term monitoring burden | Chronic endocrine follow-up may be needed. Chronic developmental and supportive monitoring may be needed. Neither course is communicable; severity labels differ. |
Patient education highlights
- HighDiagnosis confirmation
Ask which clinical findings and tests support the diagnosis; one abnormal result is not definitive.
- HighCare plan
Hormone treatment applies to the enzyme disorder; supportive therapies apply to the microduplication.
- MediumVariability
Features and needs can differ between people, especially with the chromosomal condition.